MedTrace Logo

Comparison of Three Licensed Influenza Vaccines

NCT03068949 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 413

Last updated 2021-11-30

Study results available
· View outcomes & findings →

Summary

This study will evaluate in detail the way that the immune system responds to three different kinds of flu shots that are licensed in the United States.

Conditions

Interventions

BIOLOGICAL

FluBlok

FluBlok trivalent Influenza Vaccine .5 mL given Intramuscularly

BIOLOGICAL

Fluzone

Fluzone Quadrivalent Influenza Vaccine .5 mL given intramuscularly

BIOLOGICAL

FluCelVax

FluCelVax Quadrivalent Influenza Vaccine .5 mL given intramuscularly

BIOLOGICAL

Fluzone HD

Fluzone HD Trivalent High Dose Influenza Vaccine .5 mL given intramuscularly

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Rochester

    lead OTHER

Principal Investigators

  • Angela Branche, MD · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-28
Primary Completion
2020-06-30
Completion
2021-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03068949 on ClinicalTrials.gov